ConductScience.org, home

Paper23948975

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.

Masuda H and 11 others. Clin Cancer Res, 2013. Cited by 570 papers, by iCite.

Cite this record

ConductScience Library. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Papers, record 23948975. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23948975

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
570
iCite
Relative citation ratio, by iCite
15.8
iCite
Revised in PubMed
2022-03-18
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Masuda HHiroko
2Baggerly KAKeith A
3Wang YYing
4Zhang YYa
5Gonzalez-Angulo AMAna Maria
6Meric-Bernstam FFunda
7Valero VVicente
8Lehmann BDBrian D
9Pietenpol JAJennifer A
10Hortobagyi GNGabriel N
11Symmans WFW Fraser
12Ueno NTNaoto T

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Genetic HeterogeneityMajor topic
Triple Negative Breast NeoplasmsMajor topic
Adult
Aged
Cluster Analysis
Female
Gene Expression Profiling
Humans
Middle Aged
Neoplasm Grading
Neoplasm Staging
Recurrence
Reproducibility of Results
Treatment Outcome

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP01CA016672PubMed and NIHNIH RePORTER
R01 CA123318NCI NIH HHSUnited StatesR01CA123318PubMed and NIHNIH RePORTER
CA123318NCI NIH HHSUnited StatesR01CA123318PubMed and NIHNIH RePORTER
CA016672NCI NIH HHSUnited StatesP01CA016672PubMed and NIHNIH RePORTER
P30CA016672NIHNIH RePORTER

Download CSV of grants

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117513820Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.J Clin Oncol2007https://conductscience.org/library/papers/17513820PubMed
212829800Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/12829800PubMed
317438091The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res2007https://conductscience.org/library/papers/17438091PubMed
422508812Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol2012https://conductscience.org/library/papers/22508812PubMed
520813035Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Breast Cancer Res2010https://conductscience.org/library/papers/20813035PubMed
619204204Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol2009https://conductscience.org/library/papers/19204204PubMed
719047281Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.J Clin Oncol2009https://conductscience.org/library/papers/19047281PubMed
817785706Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.J Clin Oncol2007https://conductscience.org/library/papers/17785706PubMed
916115903Breast cancer molecular subtypes respond differently to preoperative chemotherapy.Clin Cancer Res2005https://conductscience.org/library/papers/16115903PubMed
1011553815Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A2001https://conductscience.org/library/papers/11553815PubMed
1116896004Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.J Clin Oncol2006https://conductscience.org/library/papers/16896004PubMed
1221558518A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.JAMA2011https://conductscience.org/library/papers/21558518PubMed
1321421860Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.J Natl Cancer Inst2011https://conductscience.org/library/papers/21421860PubMed
1422872785TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.Cancer Inform2012https://conductscience.org/library/papers/22872785PubMed
1517387718
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Cancer2007https://conductscience.org/library/papers/17387718PubMed
1612582260Summaries of Affymetrix GeneChip probe level data.Nucleic Acids Res2003https://conductscience.org/library/papers/12582260PubMed
1720697068Genomic index of sensitivity to endocrine therapy for breast cancer.J Clin Oncol2010https://conductscience.org/library/papers/20697068PubMed
1816951390Molecular classification of breast cancer: limitations and potential.Oncologist2006https://conductscience.org/library/papers/16951390PubMed
1917493263Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.Genome Biol2007https://conductscience.org/library/papers/17493263PubMed
2018250347Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol2008https://conductscience.org/library/papers/18250347PubMed

See all 23 referencesDownload CSV of references

Cited by410

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 570 citations.

PMIDTitleJournalYearIn PapersSource
42984587Novel aptamer-based strategies for addressing aggressive and heterogeneous triple-negative breast cancer.Front Oncol2026https://conductscience.org/library/papers/42984587PubMed
42938935Clinical Challenges in Triple-Negative Breast Cancer (TNBC): Current Treatment Options, Their Limitations, and Emerging Perspectives.Cancers (Basel)2026https://conductscience.org/library/papers/42938935PubMed
42882450Distinct Mitochondrial Recovery Dynamics Following Taxol Removal in Triple-Negative Breast Cancer Cells.Cells2026https://conductscience.org/library/papers/42882450PubMed
42865910Tumor microenvironment-driven immune evasion in triple-negative breast cancer: mechanisms, clinical challenges, and therapeutic opportunities.Front Immunol2026https://conductscience.org/library/papers/42865910PubMed
42769774Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.Oncol Res2026https://conductscience.org/library/papers/42769774PubMed
42743833Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal.Breast2026https://conductscience.org/library/papers/42743833PubMed
42558411Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Front Oncol2026https://conductscience.org/library/papers/42558411PubMed
42394702Homologous recombination pathway alterations in basal-like breast cancer.Front Oncol2026https://conductscience.org/library/papers/42394702PubMed
42380524Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.Cancer Causes Control2026https://conductscience.org/library/papers/42380524PubMed
42319344Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer.Oncoimmunology2026https://conductscience.org/library/papers/42319344PubMed
42253979Spatial organization of the tumor immune microenvironment in LAR+ triple-negative breast cancer.Front Immunol2026https://conductscience.org/library/papers/42253979PubMed
42182220Integrated Collagen Architecture and Composition Improve Risk Stratification in Triple-Negative Breast Cancer.bioRxiv2026https://conductscience.org/library/papers/42182220PubMed
42093035The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer.Breast Cancer Res2026https://conductscience.org/library/papers/42093035PubMed
42033778Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma.Oncologist2026https://conductscience.org/library/papers/42033778PubMed
41977343Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer.Int J Mol Sci2026https://conductscience.org/library/papers/41977343PubMed
41975515Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer.Genome Biol2026https://conductscience.org/library/papers/41975515PubMed
41968987Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.Cancer Biol Med2026https://conductscience.org/library/papers/41968987PubMed
41889401Development and validation of an interpretable ensemble model for predicting androgen receptor status in triple-negative breast cancer: a multi-center study.Front Oncol2026https://conductscience.org/library/papers/41889401PubMed
41885969Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer.Breast Cancer Res Treat2026https://conductscience.org/library/papers/41885969PubMed
41800049The impacts of androgen receptor on treatment response and survival in triple-negative breast cancer treated with neoadjuvant chemotherapy: a single-center retrospective study.Front Oncol2026https://conductscience.org/library/papers/41800049PubMed

See all 410 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23948975

GET https://conductscience.org/api/papers/v1/23948975/references?page=2